Effective use of FibroTest to generate decision trees in hepatitis C

Abstract

AIM:To assess the usefulness of FibroTest to forecast scores by constructing decision trees in patients with chronic hepatitis C. METHODS:We used the C4.5 classification algorithm to construct decision trees with data from 261 patients with chronic hepatitis C without a liver biopsy. The FibroTest attributes of age, gender, bilirubin, apolipoprotein, haptoglobin, α2 macroglobulin, and γ-glutamyl transpeptidase were used as predictors, and the FibroTest score as the target. For testing, a 10-fold cross validation was used. RESULTS:The overall classification error was 14.9% (accuracy 85.1%). FibroTest's cases with true scores of F0 and F4 were classified with very high accuracy (18/20 for F0, 9/9 for F0-1 and 92/96 for F4) and the largest confusion centered on F3. The algorithm produced a set of compound rules out of the ten classification trees and was used to classify the 261 patients. The rules for the classification of patients in F0 and F4 were effective in more than 75% of the cases in which they were tested. CONCLUSION:The recognition of clinical subgroups should help to enhance our ability to assess differences in fibrosis scores in clinical studies and improve our understanding of fibrosis progression.

Benefits of prolonged-release pirfenidone plus standard of care treatment in patients with advanced liver fibrosis: PROMETEO study

“…Similarly, FT has been extensively evaluated in patients with chronic liver disease due to diverse etiologies and also has a high correlation biopsy findings, particularly in patients with ALF. According to Lau-Corona et al [ 28 ], FT could enhance our ability to assess differences in fibrosis scores in clinical studies and improve our understanding of fibrosis progression. Recently, Mauro et al [ 29 ], evaluated the value of portal pressure, liver stiffness, and enhanced liver fibrosis score measurements to predict fibrosis regression according to paired liver biopsies before and after sustained viral response (SVR) in recurrent HCV patients.…”

Challenges and Strategies for Access to Treatment of Hepatitis C in Latin America

“…One of the challenges with diagnosing HCV infection is that it is often asymptomatic and that individuals seek medical attention only when they develop symptoms or signs of liver disease. In Mexico, for example, the average age at diagnosis of hepatitis C is 60.7 years, and 44% of them have liver cirrhosis, indicating that patients are arriving late for diagnosis and treatment [10][11][12].…”

Hybrid Rough Genetic algorithm model for making treatment decisions of hepatitis C

“…The treatment of HCV is one of the most important issues researchers studied data mining using different Machine learning techniques for analysing and finding hidden patterns inside HCV patients' datasets and predicting the response of HCV patients to treatment. Artificial neutral network has been used to predict both Human immunodeficiency virus (HIV) and HCV proteases cleavage sites and achieved high prediction accuracy [6][7]. Finding more accurate and a simpler prediction model are considered a challenging point.…”